CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Gender Differences in Colon Cancer Treatment
-
Mar 26 2013
-
-
Source: J Womens Health (Larchmt). 22(4):344-351.
Details:
-
Alternative Title:J Womens Health (Larchmt)
-
Personal Author:
-
Description:Background
Despite women suffering a disproportionate burden of colon cancer mortality, few studies have examined gender differences in evidence-based treatment, especially in poorer states like Alabama.
Objective
To describe colon cancer treatment in older patients diagnosed in Alabama by gender.
Methods
Colon cancer patients 65 years and older diagnosed in 2000–2002 were identified from the Alabama Statewide Cancer Registry (N = 1785). Treatment was identified from Medicare claims for 1999–2003. Outcomes were (1) receipt of surgery and adjuvant 5-fluorouracil chemotherapy (5FU) and (2) 5FU treatment duration (0–4, 5–7, and >7 months). Generalized Estimating Equation (GEE) models were used to determine significant gender differences, adjusting for clustering at the reporting hospital level, and controlling for race, age, stage, comorbid conditions, census tract–level socioeconomic variables, and adverse chemotherapy effects (when analyzing 5FU duration).
Results
Overall, 93.9% of the patients received surgery. Of stage II–III patients undergoing surgery, 60.4% stage III and 25.6% stage II patients received 5FU. Compared with men, women were more likely to have surgery (95.5% vs. 92.2%, p = 0.003), less likely to have 5FU (38.6% vs. 45.2%, p = 0.02), and more likely to have 0–4 months of 5FU (32.9% vs. 24.9%, p = 0.05). Gender differences were significant for having chemotherapy (adjusted odds ratio [aOR] 0.78, confidence interval [CI] 0.61–1.00, p = 0.049), but not for having 0–4 months of 5FU when adjusting for adverse effects (aOR 1.36, CI 0.95–1.94, p = 0.09).
Conclusions
In Alabama, some gender differences in stage-specific colon cancer treatment are worth further scrutiny.
-
Subjects:
-
Source:
-
Pubmed ID:23531098
-
Pubmed Central ID:PMC4476375
-
Document Type:
-
Funding:
-
Place as Subject:
-
Volume:22
-
Issue:4
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: